▶ About us

Renhaim Inc., co-founded by EyeGene Inc. and BMI Korea, has a strategic partnership with PeproMene Bio Inc. in the U.S. Renhaim has in-licensed a novel target CAR-T therapy with an exclusive domestic right from PeproMene Bio. Renhaim is looking to recruit a cell therapy expert for further synergies with the strategic partner.

1. Position

• R&D Head of RNA-based therapeutics (Gene Therapy)
• R&D Head of Cell Therapies
• Business Development 

2. Responsibility : Please refer to the attached file.

3. Recruitment procedures : Document Screening → 1st interview → 2nd interview → Join us

Please send your CV or Resume to manager via email(ywlee@renhaim.com) to apply.

Please Visit our website (www.renhaim.com) to learn more about who we are and what we do. Thank You.